| 4.93 -0.3 (-5.74%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.61 | 1-year : | 7.49 |
| Resists | First : | 5.66 | Second : | 6.42 |
| Pivot price | 5.04 |
|||
| Supports | First : | 4.44 | Second : | 3.7 |
| MAs | MA(5) : | 4.94 |
MA(20) : | 5.11 |
| MA(100) : | 4.73  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.2 |
D(3) : | 29.6 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 6.42 | Low : | 1.38 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NEPH ] has closed above bottom band by 37.6%. Bollinger Bands are 30.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.2 - 5.23 | 5.23 - 5.25 |
| Low: | 4.76 - 4.8 | 4.8 - 4.84 |
| Close: | 4.87 - 4.93 | 4.93 - 4.98 |
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Sat, 13 Dec 2025
Nephros (NASDAQ:NEPH) Is Experiencing Growth In Returns On Capital - Sahm
Thu, 11 Dec 2025
Nephros, Inc. Launches Nephros Water Institute to Enhance Water Safety Education and Industry Leadership - Quiver Quantitative
Wed, 19 Nov 2025
Is Nephros, Inc.'s (NASDAQ:NEPH) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - simplywall.st
Fri, 07 Nov 2025
Nephros Announces Strong Third Quarter Financial Results; Achieving Highest Level of Programmatic Sales in Company History - The Manila Times
Fri, 07 Nov 2025
Nephros Inc reports results for the quarter ended September 30 - Earnings Summary - TradingView — Track All Markets
Thu, 06 Nov 2025
Earnings call transcript: Nephros Q3 2025 beats earnings forecasts, stock dips - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 11 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 11.3 (%) |
| Held by Institutions | 47.1 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | 0.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.93 |
| Profit Margin | 8.2 % |
| Operating Margin | 6.5 % |
| Return on Assets (ttm) | 7.6 % |
| Return on Equity (ttm) | 16.2 % |
| Qtrly Rev. Growth | 35.4 % |
| Gross Profit (p.s.) | 1.06 |
| Sales Per Share | 1.68 |
| EBITDA (p.s.) | 0.14 |
| Qtrly Earnings Growth | 72.9 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | 35.21 |
| PEG Ratio | 0 |
| Price to Book value | 5.24 |
| Price to Sales | 2.92 |
| Price to Cash Flow | 19.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|